Palvella Therapeutics (PVLA) Accounts Payables (2016 - 2024)
Historic Accounts Payables for Palvella Therapeutics (PVLA) over the last 12 years, with Q3 2024 value amounting to $801000.0.
- Palvella Therapeutics' Accounts Payables fell 7155.54% to $801000.0 in Q3 2024 from the same period last year, while for Sep 2024 it was $801000.0, marking a year-over-year decrease of 7155.54%. This contributed to the annual value of $936000.0 for FY2023, which is 7746.75% down from last year.
- Palvella Therapeutics' Accounts Payables amounted to $801000.0 in Q3 2024, which was down 7155.54% from $969000.0 recorded in Q2 2024.
- In the past 5 years, Palvella Therapeutics' Accounts Payables ranged from a high of $19.7 million in Q3 2021 and a low of $801000.0 during Q3 2024
- Over the past 5 years, Palvella Therapeutics' median Accounts Payables value was $6.9 million (recorded in 2020), while the average stood at $7.1 million.
- Its Accounts Payables has fluctuated over the past 5 years, first surged by 17064.96% in 2021, then crashed by 8725.67% in 2024.
- Quarter analysis of 5 years shows Palvella Therapeutics' Accounts Payables stood at $7.7 million in 2020, then rose by 11.36% to $8.6 million in 2021, then plummeted by 51.75% to $4.2 million in 2022, then crashed by 77.47% to $936000.0 in 2023, then fell by 14.42% to $801000.0 in 2024.
- Its Accounts Payables stands at $801000.0 for Q3 2024, versus $969000.0 for Q2 2024 and $1.5 million for Q1 2024.